Sichuan Kazor Biotechnology Co., Ltd. ("Kazor”) was founded in 2025 and is headquartered in the Tianfu International Bio-Town, Sichuan Province, with a total investment RMB 500 million. The company is committed to providing safe, efficient, and domestically produced critical raw materials and solutions for the cell therapy industry, promoting the application and accessibility of advanced therapeutic technologies.

The company operates a GMP-grade (compliant with NMPA standards) manufacturing facility for high-end serum-free cell therapy culture media. The core R&D team has over a decade of experience in developing cell therapy culture media and has mastered core technologies such as serum-free formulation and component restriction , ensuring stable product quality and strong batch-to-batch consistency.

Our product portfolio covers multiple stages of stem cell, immune cell, and exosome culture, preservation, cryopreservation, quality control, and auxiliary handling. We have achieved GMP-scale production of products including mesenchymal stem cell expansion media, sample preservation solutions, trilineage induction media, and cell dissociation solutions. These products significantly enhance cell viability, maintain cellular characteristics, and improve differentiation efficiency, and are widely used in drug development and regulatory filing, scientific research, and veterinary medicine for pets such as cats and dogs.

The company has established partnerships with several leading CAR-T enterprises, stem cell drug development companies, and renowned research institutions in China. In the future, Kazor will continue to invest in R&D, expand its product portfolio, and strive to become a leading supplier of critical raw materials and technologies in the cell therapy field.